Metagenomi, Inc. (MGX)
NASDAQ:MGX
Want to see MGX full AI Analyst Report?
Top Page
Metagenomi, Inc.
(NASDAQ:MGX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(1.35% Upside)
Action:ReiteratedDate:03/11/26
Score is held back primarily by persistent large losses and significant cash burn with declining equity, indicating elevated funding and execution risk. Technicals are neutral-to-mixed (short-term improvement but long-term downtrend), while valuation is difficult to support given negative earnings and no dividend. Corporate updates are constructive, especially the extended runway and pipeline milestones, but do not offset weak financial performance.
Positive Factors
Extended cash runway
A stated capital allocation plan extending runway through Q4 2027 materially reduces near-term financing pressure, giving management time to advance programs and secure partnerships. That durability lowers immediate dilution risk and supports execution on multi-stage therapeutic milestones.
Negative Factors
Persistent heavy cash burn
Sustained negative operating and free cash flow of roughly -$89M in 2025 evidences high cash consumption tied to R&D and operations. Over the next several quarters this elevates refinancing and dilution risk unless milestone revenues or partnerships materialize, constraining strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway
A stated capital allocation plan extending runway through Q4 2027 materially reduces near-term financing pressure, giving management time to advance programs and secure partnerships. That durability lowers immediate dilution risk and supports execution on multi-stage therapeutic milestones.
Read all positive factors
Metagenomi, Inc. (MGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$53.04M
Dividend YieldN/A
Average Volume (3M)883.52K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth-51.79%
EPS Growth9.77%
CountryUS
Employees202
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.37
Shares Outstanding37,620,530
10 Day Avg. Volume1,405,864
30 Day Avg. Volume883,524
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.38
Price to Sales (P/S)2.39
P/FCF Ratio-0.67
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit657.97
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$9.50Price Target Upside541.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.09
Revenue Forecast (FY)$26.23M
Metagenomi, Inc. Business Overview & Revenue Model
Company Description
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, ...
How the Company Makes Money
Metagenomi’s revenue model is primarily based on partnering and licensing its gene-editing platform and related intellectual property to other life-science companies. Key revenue streams typically include (1) upfront payments received when enterin...
Metagenomi, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.21M | 52.30M | 44.76M | 17.20M | 243.00K |
| Gross Profit | 19.89M | 52.30M | -49.65M | 15.47M | -144.00K |
| EBITDA | -90.70M | -83.49M | -74.28M | -39.19M | -20.75M |
| Net Income | -87.87M | -78.06M | -68.25M | -43.59M | -21.44M |
Balance Sheet | |||||
| Total Assets | 221.10M | 324.60M | 364.84M | 414.49M | 141.99M |
| Cash, Cash Equivalents and Short-Term Investments | 160.80M | 248.31M | 271.18M | 362.13M | 108.15M |
| Total Debt | 40.66M | 45.78M | 48.23M | 18.57M | 48.93M |
| Total Liabilities | 62.51M | 89.74M | 149.67M | 488.91M | 174.54M |
| Stockholders Equity | 158.60M | 234.86M | 215.17M | -74.43M | -32.54M |
Cash Flow | |||||
| Free Cash Flow | -89.47M | -112.19M | -101.22M | 15.75M | 21.35M |
| Operating Cash Flow | -88.89M | -109.07M | -91.41M | 29.72M | 24.26M |
| Investing Cash Flow | 103.53M | -88.16M | 45.73M | -122.20M | -74.32M |
| Financing Cash Flow | -356.00K | 84.01M | 1.01M | 239.59M | 39.92M |
Metagenomi, Inc. Technical Analysis
Positive
1.48
Price Trends
1.47
Positive
1.57
Negative
1.89
Negative
Market Momentum
-0.01
Negative
56.67
Neutral
78.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.47, and below the 200-day MA of 1.89, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 56.67 is Neutral, neither overbought nor oversold. The STOCH value of 78.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGX.
Metagenomi, Inc. Risk Analysis
Metagenomi, Inc. disclosed 78 risk factors in its most recent earnings report. Metagenomi, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Metagenomi, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $165.42M | 1.39 | 43.14% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $158.42M | -1.08 | -1197.81% | ― | ― | 27.88% | |
47 Neutral | $53.04M | -0.68 | -47.14% | ― | -51.79% | 9.77% | |
47 Neutral | $218.67M | -7.18 | -59.95% | ― | ― | -24.56% | |
43 Neutral | $70.99M | -16.66 | -79.12% | ― | -6.33% | ― | |
40 Underperform | $33.05M | -0.75 | -158.81% | ― | -100.00% | 26.30% |
* Healthcare Sector Average
MGX
Metagenomi, Inc.
1.41
-0.14
-9.03%
ORMP
Oramed Pharm
4.09
2.00
95.88%
IMUX
Immunic
11.63
1.76
17.87%
ATRA
Atara Biotherapeutics
8.34
1.87
28.90%
HOWL
Werewolf Therapeutics
0.68
-0.32
-32.00%
CNTX
Context Therapeutics
2.38
1.60
205.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.